Next Investors logo grey

Creso Pharma launch into $30 billion Asian health food market


Published 20-NOV-2017 09:35 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma (ASX:CPH) today announced it had entered into a strategic partnership and commercial distribution agreement with Hong Kong listed Zhejiang Kingdom Creative Co., Ltd (HKG:0528).

The agreement with the HK$623.38 million (AU$90.6M) capped company gives Creso access to the lucrative Chinese healthcare sector.

Kingdom is a hemp and flax-based linen production company, located in China’s Zhejiang province and is looking to expand its product offering into the healthcare sector.

The partnership with Creso is thus mutually beneficial as Kingdom draws on Creso’s expertise in hemp- and cannabis-based nutraceutical and medicinal cannabis therapeutics and products. Kingdom will use the partnership to vertically integrate beyond textiles and diversify into value-added, hemp-based nutraceuticals for human and animal health as well as cosmetics and beauty products.

The two companies will collaborate to distribute hemp- and cannabis-based products for human and animal health as well as cosmetics, body care and medicinal cannabis products across China.

The Chinese health food market is currently valued at RMB200 billion (US$30 billion) and is projected to grow by 10 per cent every year to 2025. The market includes vitamins, dietary supplements and minerals, animal and herbal extracts and traditional Chinese medicine.

According to some reports, China is becoming the world’s largest market for healthy eating.

China is also the world’s largest producer of pharma ingredients and the world’s second-largest pharma market. It is projected to reach US$158 billion worldwide in 2016 and grow at a CAGR 7.7% between 2014 and 2019.

Sales for medical cannabis in China are also expected to grow with China progressively opening up legislation to allow hemp-based and medical cannabis products to be available to patients.

“This is a very exciting partnership for Creso as it gives us a strategic foothold in China and Asia. Our collaboration with Kingdom offers a great opportunity to work with a well-established and substantial organisation in this market,” said Creso Pharma CEO and Co‐Founder, Dr. Miri Halperin Wernli.

How much of this market, Creso is able to attract remains to be seen and investors should seek professional financial advice if considering this stock for their portfolio.

Creso has been working hard behind the scenes in Asia to create a first mover advantage and has opened four offices in China: Beijing, Shanghai, Shenzhen and Guangzhou.

Entry into China, gives Creso a sales and marketing presence and local distribution network for its products as well as platform to launch into the broader Asian region.

Creso and Kingdom will enter into a definitive agreement within three months of execution to further define the collaboration and commercial terms, including consideration of expansion into additional territories.

“The opening up of four offices in major Chinese cities strongly augments this agreement (with Kingdom) and gives the partnership additional sales and marketing support and our own local distribution network. We will use this presence to expand into other strategic Asian markets,” Dr. Halperin Wernli said.

The partnership with Kingdom is just the start of the company’s Asian expansion.

Creso is in advanced discussions with other Asian pharmaceutical and cosmetic groups to bring its products and IP to Asia in a fast, effective and efficient manner to be able to reach a massive population of consumers and patients.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.